Interaction of the Aryl Hydrocarbon Receptor Ligand 6-Methyl-1,3,8-trichlorodibenzofuran with Estrogen Receptor α

Cancer Research

Volumn 64, Issue 8, 2004, Pages 2889-2897

  Pearce, Sandra Timm ^a   Liu, Hong ^a   Radhakrishnan, Ishwar ^b   Abdelrahim, Maen ^c   Safe, Stephen ^c   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,8 TRICHLORO 6 METHYLDIBENZOFURAN; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTIESTROGEN; AROMATIC HYDROCARBON RECEPTOR; DIOXIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GLUTATHIONE TRANSFERASE; LIGAND; LUCIFERASE; MESSENGER RNA; POLYCYCLIC AROMATIC HYDROCARBON; SMALL INTERFERING RNA; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA;

AGONIST; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG SPECIFICITY; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; KNOCKOUT GENE; LIGAND BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REPORTER GENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; UTERUS;

BENZOFURANS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HUMANS; MODELS, MOLECULAR; RECEPTOR CROSS-TALK; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, ESTROGEN; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 7744233016     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1770     Document Type: Article

References (56)

1. Safe S. Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 2001;120:1-7.
2. Safe S, Wang F, Porter W, Duan R, McDougal A. Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms. Toxicol Lett 1998;102-3:343-7.
3. Safe S, Astroff B, Harris M, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related compounds as antioestrogens: characterization and mechanism of action. Pharmacol Toxicol 1991;69:400-9.
4. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001;61:5683-7.
5. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst (Bethesda) 2001;93:1449-57.
6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (Bethesda) 1998;90:1371-88.
7. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 1999;35:1974-85.
8. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992;89:4037-41.
9. Howell A, Robertson IF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20: 3396-403.
10. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95.
11. Safe S, McDougal A. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (review). Int J Oncol 2002;20:1123-8.
12. Zacharewski T, Harris M, Biegel L, et al. 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: evidence for the role of the Ah receptor. Toxicol Appl Pharmacol 1992;113:311-8.
13. Sun G, Safe S. Antiestrogenic activities of alternate-substituted polychlorinated dibenzofurans in MCF-7 human breast cancer cells. Cancer Chemother Pharmacol 1997;40:239-44.
14. Astroff B, Safe S. Comparative antiestrogenic activities of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 6-methyl-1,3,8-trichlorodibenzofuran in the female rat. Toxicol Appl Pharmacol 1988;95:435-43.
15. McDougal A, Wilson C, Safe S. Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett 1997;120:53-63.
16. Wormke M, Stoner M, Saville B, Safe S. Crosstalk between estrogen receptor α and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. FEBS Lett 2000;478:109-12.
17. McDougal A, Wormke M, Calvin J, Safe S. Tamoxifen-induced antitumorigenic/ antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator. Cancer Res 2001;61:3902-7.
18. MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW, Jordan VC. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000; 60:5097-105.
19. Liu H, Lee ES, Deb Los Reyes A, Zapf JW, Jordan VC. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor α complex. Cancer Res 2001;61:3632-9.
20. Jordan VC, Schafer JM, Levenson AS, et al. Molecular classification of estrogens. Cancer Res 2001;61:6619-23.
21. Pearce ST, Liu H, Jordan VC. Modulation of estrogen receptor α function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem 2003;278:7630-8.
22. Ohtake F, Takeyama K, Matsumoto T, et al. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature (Lond) 2003;423: 545-50.
23. Jiang SY, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst (Bethesda) 1992;84:580-91.
24. Pink JJ, Bilimoria MM, Assikis J, Jordan VC. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer 1996:74:1227-36.
25. Astroff B, Safe S. 6-Substituted-1,3,8-trichlorodibenzofurans as 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonists in the rat: structure activity relationships. Toxicology 1989;59:285-96.
26. La Barca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 1980;102:344-52.
27. Catherino WH, Jordan VC. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 1995;92:39-47.
28. Hanstein B, Eckner R, DiRenzo J, et al. p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 1996;93:11540-5.
29. Tanenbaum DM, Wang Y, Williams SP, Sigler PB. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA 1998;95:5998-6003.
30. Halachmi S, Marden E, Martin G, et al. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science (Wash DC) 1994;264: 1455-8.
31. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (Wash DC) 1997;277:965-8.
32. Abdelrahim M, Smith R III, Safe S. Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells. Mol Pharmacol 2003;63:1373-81.
33. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 1999;96:1858-62.
34. El Khissiin A, Leclercq G. Implication of proteasome in estrogen receptor degradation. FEBS Lett 1999;448:160-6.
35. Alarid ET, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 1999; 13:1522-34.
36. Wijayaratne AL, McDonnell DP. The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001;276:35684-92.
37. Wormke M, Stoner M, Saville B, et al. The aryl hydrocarbon receptor mediates degradation of estrogen receptor α through activation of proteasomes. Mol Cell Biol 2003;23:1843-55.
38. Thomsen JS, Wang X, Hines RN, Safe S. Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. Carcinogenesis (Lond) 1994;15:933-7.
39. Gaido KW, Maness SC, Leonard LS, Greenlee WF. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-dependent regulation of transforming growth factors-α and -β2 expression in a human keratinocyte cell line involves both transcriptional and post-transcriptional control. J Biol Chem 1992;267:24591-5.
40. Liu H, Wormke M, Safe SH, Bjeldanes LF. Indolo[3,2-b]carbazole: a dietary-derived factor that exhibits both antiestrogenic and estrogenic activity. J Natl Cancer Inst (Bethesda) 1994;86:1758-65.
41. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001;81:1535-65.
42. Dickerson R, Keller LH, Safe S. Alkyl polychlorinated dibenzofurans and related compounds as antiestrogens in the female rat uterus: structure-activity studies. Toxicol Appl Pharmacol 1995;135:287-98.
43. Kumar MB, Tarpey RW, Perdew GH. Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. J Biol Chem 1999;274:22155-64.
44. Klinge CM, Bowers JL, Kulakosky PC, Kamboj KK, Swanson HI. The aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT) heterodimer interacts with naturally occurring estrogen response elements. Mol Cell Endocrinol 1999;157:105-19.
45. Pike AC, Brzozowski AM, Hubbard RE. A structural biologist's view of the oestrogen receptor. J Steroid Biochem Mol Biol 2000;74:261-8.
46. van Hoorn WP. Identification of a second binding site in the estrogen receptor. J Med Chem 2002;45:584-9.
47. Wang Y, Chirgadze NY, Briggs SL, et al. A second binding site for hydroxytamoxifen within the ligand-binding domain of estrogen receptor beta. In: Proceedings of the 85th Annual Endocrine Society Meeting, Abstract No. OR34-2. Chevy Chase, MD: The Endocrine Society Press; 2003. p. 106.
48. Gee AC, Carlson KE, Martini PG, Katzenellenbogen BS, Katzenellenbogen JA. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol Endocrinol 1999;13: 1912-23.
49. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997; 138:863-70.
50. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998;139:4252-63.
51. Bentrem D, Fox JE, Pearce ST, et al. Distinct molecular conformations of the estrogen receptor α complex exploited by environmental estrogens. Cancer Res 2003;63:7490-6.
52. Sathyamoorthy N, Wang T, Phang J. Stimulation of pS2 expression by diet-derived compounds. Cancer Res 1994;54:957-61.
53. Miksicek R. Estrogenic flavonoids: structural requirements for biological activity. Proc Soc Exp Biol Med 1995;208:44-50.
54. Breinholt V, Larsen JC. Detection of weak estrogenic flavonoids using a recombinant yeast strain and a modified MCF7 cell proliferation assay. Chem Res Toxicol 1998;11:622-9.
55. Ciolino HP, Daschner PJ, Yeh GC. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem J 1999;340:715-22.
56. Zhang S, Qin C, Safe S. Flavonoids as aryl hydrocarbon receptor agonists/antagonists effects of structure and cell context. Environ Health Perspect 2003; 111:1877-82.